Table 2.
Factors associated with progression-free survival in 87 patients with hepatocellular carcinoma
| Character | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
|
|
|
||||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (year) | 0.991 (0.967-1.015) | .453 | |||
| Sex | Female vs male | 0.898 (0.407-1.982) | .790 | ||
| Alcohol | No vs yes | 1.174 (0.661-2.086) | .583 | ||
| HBV | No vs yes | 0.916 (0.552-1.518) | .733 | ||
| HCV | No vs yes | 0.830 (0.461-1.495) | .535 | ||
| Grade 1-2 irAEs | Yes vs no | 2.042 (1.138-3.664) | .017 | ||
| Grade ≥3 irAEs | Yes vs no | 1.032 (0.536-1.990) | .924 | ||
| TTV (cm3) | ≤1000 vs >1000 | 2.118 (1.274-3.523) | .004 | ||
| Tumor number | Single vs multiple | 2.995 (1.462-6.135) | .003 | ||
| MVI | No vs yes | 2.388 (1.3734.153) | .002 | 4.266 (1.822-9.988) | .001 |
| EHM | No vs yes | 1.497 (0.887-2.528) | .131 | ||
| CLIP score | 0-2 vs ≥3 | 3.967 (2.243-7.015) | <.001 | ||
| AFP (ng/mL) | <400 vs ≥400 | 0.959 (0.573-1.606) | .874 | ||
| NLR | ≤3.0 vs >3.0 | 2.530 (1.147-5.582) | .021 | ||
| AST (U/L) | ≤40 vs >40 | 2.274 (1.020-5.066) | .045 | ||
| ALT (U/L) | ≤40 vs >40 | 2.010 (1.155-3.500) | .014 | ||
| Child-Pugh class | A vs B/C | 1.905 (1.139-3.186) | .014 | ||
| ALBI grade | 1 vs 2/3 | 1.867 (0.966-3.607) | .063 | ||
| Prior therapy | |||||
| Sorafenib | No vs yes | 0.948 (0.573-1.567) | .835 | ||
| Lenvatinib | No vs yes | 1.100 (0.498-2.428) | .814 | ||
| Concurrent therapy | No vs yes | 0.261 (0.151-0.451) | <.001 | 0.107 (0.046-0.248) | <.001 |
| TKI | No vs yes | 0.472 (0.274-0.814) | .007 | ||
| TACE | No vs yes | 0.354 (0.141-0.888) | .027 | ||
| Radiotherapy | No vs yes | 1.685 (0.751-3.779) | .206 | ||
| AFP response | Yes vs No | 2.853 (1.502-5.422) | .001 | 3.454 (1.631-7.317) | .001 |
| Best response | CR + PR vs none | 4.166 (1.942-8.936) | <.001 | ||
AFP, α-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLIP, Cancer of the Liver Italian Program; CR + PR, complete response plus partial response; EHM, extrahepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; irAEs, immune-related adverse events; MVI, macroscopic vascular invasion; NLR, neutrophil-lymphocyte ratio; TACE, transarterial chemoembolization; TKI, tyrosine kinase inhibitor; TTV, total tumor volume.